Rybelsus® reduced major adverse cardiovascular events by 14% vs placebo in adults with type 2 diabetes and cardiovascular and/or chronic kidney disease in the SOUL cardiovascular outcomes trial1. Data were presented at the American College of Cardiology's (ACC) Annual...Read more
Lorundrostat 50 mg dose achieved a 15.4 mmHg absolute reduction and 7.9 mmHg placebo-adjusted reduction (p=0.001), assessed by 24hr ABPM at week 12, with favorable safety and tolerability profile Lorundrostat is a highly selective aldosterone synthase inhibitor that disrupts...Read more
New Data Follow Recent U.S. FDA Approval of AMVUTTRA® (vutrisiran) as First RNAi Therapeutic to Reduce Cardiovascular Death, Cardiovascular Hospitalizations and Urgent Heart Failure Visits in Patients with ATTR-CM Vutrisiran Favorably Impacted Echocardiographic Systolic and...Read more
Qfitlia Becomes the Sixth Alnylam-Discovered RNAi Therapeutic Approved by U.S. FDA and First and Only to Treat Hemophilia A or B With or Without Inhibitors CAMBRIDGE, Mass. / Mar 28, 2025 / Business Wire / Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company,...Read more
MORRISVILLE, N.C., March 28, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug...Read more
CRL focused on CMC; no clinical issues relating to etripamil raised $69.7M in cash, cash equivalents and short-term investments as of December 31, 2024 MONTREAL and CHARLOTTE, N.C., March 28, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced...Read more
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE| Company | Change | Last Trade |
|---|---|---|
| Aclarion | 11.37 1,516.00 | $12.12 |
| Portage Biotech | 4.89 103.82 | $9.60 |
| Soleno Therapeutics | 4.60 6.83 | $71.99 |
| McKesson | 2.39 0.36 | $668.06 |
| DBV Technologies | 2.21 56.52 | $6.12 |
| OpGen | 2.09 110.00 | $3.99 |
| PureTech Health | 1.64 9.27 | $19.34 |
| Merck | 1.63 1.86 | $89.23 |
| Regeneron Pharmaceuticals | 1.53 0.24 | $637.36 |
| Acadia Healthcare | 1.43 4.98 | $30.12 |
| Quest Diagnostics | 1.33 0.80 | $167.33 |
| Rhythm Pharmaceuticals | 1.31 2.45 | $54.80 |
| Orgenesis | 1.26 59.72 | $3.37 |
| AbbVie | 1.21 0.59 | $205.29 |
| Amgen | 1.18 0.39 | $306.95 |
| Krystal Biotech | 1.17 0.64 | $183.92 |
| Novartis | 1.17 1.05 | $112.57 |
| Actuate Therapeutics | 1.15 17.04 | $7.90 |
| Company | Volume | Last Trade |
|---|---|---|
| Lexicon Pharmaceuticals | 400,331,507 | $0.57 |
| Sharps Technology | 201,142,043 | $0.04 |
| Sensei Biotherapeutics | 144,800,081 | $0.50 |
| Ocean Biomedical | 43,954,171 | $0.06 |
| Milestone Pharmaceuticals | 33,133,274 | $0.88 |
| Pfizer | 31,485,637 | $25.21 |
| Portage Biotech | 29,686,985 | $9.60 |
| 23andMe | 27,698,468 | $0.61 |
| TransCode Therapeutics | 22,614,387 | $0.50 |
| DBV Technologies | 21,652,054 | $6.12 |
| Petros Pharmaceuticals | 18,413,576 | $0.09 |
| Geron | 16,139,453 | $1.65 |
| Recursion | 14,889,153 | $5.81 |
| Palatin Technologies | 14,789,513 | $0.66 |
| Quantum BioPharma | 14,070,448 | $8.52 |
| PacBio | 12,286,891 | $1.14 |
| Walgreens Boots Alliance | 11,959,670 | $11.17 |
| Merck | 11,928,310 | $89.23 |
| Humacyte | 11,889,914 | $1.96 |
Recursion is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological and chemical datasets...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Assertio is a leading commercial pharmaceutical company bringing differentiated products to patients. The Company has a robust portfolio of branded prescription products in three areas: neurology, hospital, and pain and inflammation. Assertio has grown through...
CLICK TO LEARN MORE
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders, with three compounds currently in clinical trials. Viking’s research and development activities leverage...
CLICK TO LEARN MORE
